Christina Dickson

1.3k total citations · 3 hit papers
13 papers, 931 citations indexed

About

Christina Dickson is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Christina Dickson has authored 13 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 4 papers in Genetics and 4 papers in Hematology. Recurrent topics in Christina Dickson's work include Rheumatoid Arthritis Research and Therapies (7 papers), Systemic Lupus Erythematosus Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Christina Dickson is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Systemic Lupus Erythematosus Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Christina Dickson collaborates with scholars based in United States, Japan and United Kingdom. Christina Dickson's co-authors include Tsutomu Takeuchi, Terence Rooney, William L. Macias, Josef S Smolen, Roy Fleischmann, Mark C. Genovese, Kevin Winthrop, Douglas Schlichting, David L. Hyslop and Sirel Gurbuz and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

In The Last Decade

Christina Dickson

12 papers receiving 909 citations

Hit Papers

Baricitinib, Methotrexate, or Combination in Patients Wit... 2016 2026 2019 2022 2016 2023 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Roy Fleischmann, Michael Schiff et al. Arthritis & Rheumatology profile →
  2. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
    2023 89 citations Michelle Petri, Ian N Bruce et al. The Lancet profile →
  3. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    2023 79 citations Eric F. Morand, Edward M Vital et al. The Lancet profile →

Peers

Christina Dickson
M. C. Genovese United States
Jeffrey Neal United States
Kahaku Emoto Japan
Emma Vernon United States
Myrna Cardiel United States
Naonobu Sugiyama Japan
Alba Erra Spain
Daniel Siri Argentina
Nilzio A Da Silva Brazil
Jean Tayar United States
M. C. Genovese United States
Christina Dickson
Citations per year, relative to Christina Dickson Christina Dickson (= 1×) peers M. C. Genovese

Countries citing papers authored by Christina Dickson

Since Specialization
Citations

This map shows the geographic impact of Christina Dickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Dickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Dickson more than expected).

Fields of papers citing papers by Christina Dickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Dickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Dickson. The network helps show where Christina Dickson may publish in the future.

Co-authorship network of co-authors of Christina Dickson

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Dickson. A scholar is included among the top collaborators of Christina Dickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Dickson. Christina Dickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Brunner, Hermine I., Aisha Vadhariya, Christina Dickson, et al.. (2023). Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Science & Medicine. 10(2). e000817–e000817. 10 indexed citations
2.
Morand, Eric F., Josef S Smolen, Michelle Petri, et al.. (2023). Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open. 9(3). e003302–e003302. 5 indexed citations
3.
Petri, Michelle, Ian N Bruce, Thomas Dörner, et al.. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). The Lancet. 401(10381). 1011–1019. 89 indexed citations breakdown →
4.
Morand, Eric F., Edward M Vital, Michelle Petri, et al.. (2023). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). The Lancet. 401(10381). 1001–1010. 79 indexed citations breakdown →
5.
Bosworth, Hayden B., Christina Dickson, Jennifer M. Gierisch, et al.. (2023). A telehealth-delivered intervention to extend the veteran HIV treatment cascade for cardiovascular disease prevention: V-EXTRA-CVD study protocol for a randomized controlled trial. SHILAP Revista de lepidopterología. 24(1). 2261747–2261747.
6.
Pope, Janet, Yvonne Lee, Jeffrey R. Curtis, et al.. (2021). Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. ACR Open Rheumatology. 4(3). 254–258. 3 indexed citations
7.
Winthrop, Kevin, Masayoshi Harigai, Mark C. Genovese, et al.. (2020). Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 79(10). 1290–1297. 66 indexed citations
8.
Harigai, Masayoshi, Kevin Winthrop, Tsutomu Takeuchi, et al.. (2020). Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 6(1). e001095–e001095. 56 indexed citations
9.
Kay, Jonathan, Masayoshi Harigai, Christina Dickson, et al.. (2020). Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 6(3). e001370–e001370. 30 indexed citations
10.
Michaud, Kaleb, Janet Pope, Paul Emery, et al.. (2019). Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatology and Therapy. 6(3). 409–419. 19 indexed citations
11.
Taylor, Peter C., Yvonne Lee, Roy Fleischmann, et al.. (2019). Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of Clinical Medicine. 8(6). 831–831. 59 indexed citations
12.
Smolen, Josef S, Mark C. Genovese, Tsutomu Takeuchi, et al.. (2018). Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. The Journal of Rheumatology. 46(1). 7–18. 206 indexed citations
13.
Fleischmann, Roy, Michael Schiff, Désirée van der Heijde, et al.. (2016). Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment. Arthritis & Rheumatology. 69(3). 506–517. 309 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. C. Genovese Breakdown of academic impact, for papers by Jeffrey Neal Breakdown of academic impact, for papers by Kahaku Emoto Breakdown of academic impact, for papers by Emma Vernon Breakdown of academic impact, for papers by Myrna Cardiel Breakdown of academic impact, for papers by Naonobu Sugiyama Breakdown of academic impact, for papers by Alba Erra Breakdown of academic impact, for papers by Daniel Siri Breakdown of academic impact, for papers by Nilzio A Da Silva Breakdown of academic impact, for papers by Jean Tayar
Rankless by CCL
2026